Search | Clinical Trials Finder

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Interferon beta-1b, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • San Diego, California + 3 more

Conditions: Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more

Conditions: Colitis, HIV Infections
Interventions: Glutamic acid hydrochloride, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more

Conditions: Congenital CMV Infection, Sensorineural Hearing Loss
Interventions: Not listed
Lead sponsor: Stony Brook University; Other
Eligibility: 0 Days to 1 Year
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Birmingham, Alabama • Oakland, California • San Francisco, California + 5 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: Chiron Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: rAAV2.5-CMV-minidystrophin (d3990); Biological
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 5 Years to 15 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Congenital Cytomegalovirus Infection
Interventions: Letermovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 90 Days
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin

Conditions: Cytomegalovirus Infections
Interventions: ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 1 Month
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Diego, California + 12 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Roche Global Development; Other
Eligibility: 13 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 16 more

Conditions: Congenital CMV Infection
Interventions: Education of parents to pursue prompt hearing screening.; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 24 Hours to 14 Days
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Bellevue, Nebraska • Omaha, Nebraska

Conditions: Maternal Cytomegalovirus Infections, Cytomegalovirus Congenital
Interventions: CMV Risk-Reduction Intervention, Stress Reduction Messaging; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 39 Years · Female only
Enrollment: 582 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Interventions: viral specific cytotoxic t-lymphocytes; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Month to 79 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 6 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Bacterial Infections, Acute Viral Infections
Interventions: Not listed
Lead sponsor: The Plasma Source; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Southampton, Pennsylvania

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Cidofovir, Probenecid, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Los Angeles, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Cytomegalovirus Infections
Interventions: CMV PCR on saliva; Diagnostic Test
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 1 Day to 36 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Cytomegalovirus Infections, Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist, Mechanical Ventilation
Interventions: NAVA, CMV; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 24 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Providence, Rhode Island

Conditions: Cytomegalovirus Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 14 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Zidovudine, Didanosine, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Irvine, California • Washington D.C., District of Columbia • Galveston, Texas

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Berkeley, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Search by objective public record fields.

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

Long-Term Outcomes of Children With Congenital CMV in New York State

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy

A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis

Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit

Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

300 Antibody Diagnostic Test Kit

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study

Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

NAVA vs. CMV Crossover in Severe BPD

Neonatal CMV-Ganciclovir Follow-up Study

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS